Phage therapy for cystic fibrosis with pseudomonas lung infection
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests a new treatment using phages (viruses that kill bacteria) for people with cystic fibrosis who have a chronic pseudomonas lung infection. It aims to see if adding phages to your usual care can help control the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cystic fibrosis and a long-term pseudomonas lung infection
- You are 18 years or older
- Your lung function (FEV1) is between 40% and 80% of normal
- Your lung disease is stable (no recent worsening)
- You can provide sputum samples (phlegm) for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cocktail of viruses (bacteriophages) that target achromobacter bacteria in the lungs of adults with cystic fibrosis. It aims to see if the phages are safe and can reduce the infection.
This trial tests an inhaled mRNA therapy (BMD003) for adults with cystic fibrosis. It aims to see if the treatment is safe and can help improve lung function.
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
This trial tests whether adding a special virus (bacteriophage) that kills antibiotic-resistant bacteria to standard IV antibiotics is safe for people with cystic fibrosis. It is for adults whose lung infections are hard to treat because the bacteria have stopped responding to usual antibiotics.
This trial tests whether bacteriophages—viruses that kill bacteria—can help treat a chronic lung infection caused by a drug-resistant bacterium called Mycobacterium abscessus.
This is a special program for one patient with a lung infection from Mycobacterium abscessus. The trial uses a treatment with bacteriophages, which are viruses that attack specific bacteria.
Hear when a new Chronic Pseudomonas Aeruginosa Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.